BioCardia Inc.

BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brands. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioCardia reports successful fiscal year with promising clinical trials

BioCardia Inc. had a strong fiscal year with positive clinical trial results and increased revenues. While facing challenges related to trial data and timelines, the company's diversified product pipeline and financial stability offer growth opportunities in the healthcare sector.

BioCardia advances cell therapy programs amidst financial challenges and opportunities

BioCardia's Q1 2023 performance reflects ongoing investment in innovative cell therapy platforms. While facing financial challenges, the company remains focused on advancing clinical trials and engaging with regulatory authorities. Opportunities exist for BioCardia to leverage its expertise in cell therapy for strategic partnerships and further development.

BioCardia reports Q2 progress amidst trial setback and regulatory advancements

BioCardia's Q2 performance reflects progress in cell therapy platforms and regulatory advancements.
While facing challenges with the CardiAMP trial pause, the company maintains transparency and commitment to stakeholders.
Opportunities lie in addressing trial concerns, improving financial performance, and expanding market reach.

BioCardia reports Q3 results, progresses in cell therapy trials

BioCardia's Q3 performance reflects a mix of financial challenges and promising advancements in cell therapy trials for cardiovascular diseases.
Despite setbacks like the pause in the CardiAMP trial, the company's strategic initiatives and focus on regulatory approvals signal resilience and growth potential.
With a proactive approach to trial modifications and business development, BioCardia aims to leverage opportunities for future success in the biotech sector.

BioCardia reports positive trial data and strategic growth initiatives

BioCardia's Q4 2023 earnings call highlighted positive trial data, financial performance, strategic partnerships, and regulatory advancements, positioning the company for future growth.
While facing challenges in funding, timelines, and regulatory compliance, BioCardia's focus on innovation and market expansion presents opportunities for long-term success.
Investors should monitor BioCardia's progress in advancing its cell therapy platforms, securing approvals, and navigating regulatory landscapes for insights into its growth trajectory.

BioCardia reports positive trial results and financial improvements in Q1

BioCardia's Q1 2024 performance showcased positive trial results and improved financials, setting the stage for potential regulatory submissions and commercialization strategies.
While facing challenges in regulatory discussions and trial advancements, the company remains poised to capitalize on opportunities for growth and expansion.

BioCardia reports positive Q2 earnings, advances heart failure treatments

BioCardia demonstrated improved financial performance and significant advancements in clinical trials and product development, positioning the company for future growth
While facing challenges in regulatory compliance and financial sustainability, BioCardia's strengths in innovative treatments and partnership opportunities offer avenues for expansion
The company's focus on achieving key milestones like FDA clearances and trial completions underscores its commitment to advancing cardiovascular therapies and enhancing shareholder value

BioCardia reports strong Q3 performance, eyes partnerships for growth

BioCardia's Q3 2024 performance reflects improved financials and promising advancements in their lead cell therapy programs for heart failure
The company's strengths lie in efficient capital management, pipeline progress, and successful fundraising activities, positioning them for future growth
Challenges include clinical trial outcomes, regulatory hurdles, and balancing R&D momentum with cost management, while opportunities exist in partnerships and market expansion

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

BioCardia has a leading-edge cardiac cell therapy platform. The company recently announced a settlement Term Sheet with Boston Scientific, BSX.

BioCardia Is Super Cheap With Multiple Shots On Goal

SAN CARLOS, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, announces that CEO Dr. Peter Altman will present at Maxim Group's Inaugural Emerging Growth Virtual Conference to be held March 17-19, 2021.

BioCardia to Present at Maxim Group's Inaugural Emerging Growth Virtual Conference

SAN CARLOS, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced clinical leadership changes.

BioCardia Announces Clinical Leadership Changes

SAN CARLOS, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today provides an update on its cell therapy product development and 2021 milestones.

BioCardia Update on Cell Therapy Product Development and 2021 Milestones

SAN CARLOS, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, welcomes Krisztina Zsebo, Ph.D., a 31-year veteran of the biotech industry, to its Board of Directors following her election at BioCardia's 2020 Annual Meeting of Stockholders in December 2020.

Accomplished Biotech Executive Krisztina Zsebo, Ph.D. Joins BioCardia's Board of Directors

Altimmune

Incyte

Altimmune (NASDAQ: ALT) shares were trading higher Wednesday after the company announced it began a multinational Phase 2 clinical trial of HepTcellTM for the treatment of chronic Hepatitis B. Altimmune is a U.S.-based, clinical-stage immunotherapeutic biotechnology company.

Why These Health Care Stocks Are Moving Today

Technology Anticipated to Impact Cardiac Biologic Therapies, Cardiac Arrhythmia, and Structural Heart Procedures Technology Anticipated to Impact Cardiac Biologic Therapies, Cardiac Arrhythmia, and Structural Heart Procedures

BioCardia Issued New U.S. Patent for Technology that Enhances Control for Cardiac Therapies

SAN CARLOS, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP™ Heart Failure Trial. The DSMB based its review on all available data for the 86 patients enrolled in the trial, including 60 randomized patients who have reached their one-year follow-up. The DSMB performed a risk-benefit assessment, indicated no safety concerns, and recommended that the study continue as designed.

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Heart Failure Study as Designed

Shares of BioCardia Inc. sank 13.9% in morning trading Wednesday, after the developer of regenerative biologic therapies announced more stock sales in the wake of the 137.6% rocket ride over the past two days. The company said before Wednesday's open that it sold 2.04 million shares of its stock at $5.15 a share in a registered direct offering to raise $10.5 million, On Monday, the company said it sold 1.79 million shares at $4.75 a share in a registered direct offering to raise $8.5 million.

BioCardia's stock pulls back after taking advantage of recent doubling with another share sale

SAN CARLOS, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA) (BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the purchase and sale of 2,038,836 shares of its common stock at a purchase price of $5.15 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about December 18, 2020, subject to the satisfaction of customary closing conditions.

BioCardia, Inc. Announces $10.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SAN CARLOS, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the purchase and sale of 1,789,474 shares of its common stock at a purchase price of $4.75 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about December 16, 2020, subject to the satisfaction of customary closing conditions.

BioCardia, Inc. Announces $8.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules [Revised]

SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the purchase and sale of 1,888,889 shares of its common stock at a purchase price of $4.75 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about December 16, 2020, subject to the satisfaction of customary closing conditions.

BioCardia, Inc. Announces $8.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

BioCardia (BCDA) news for Monday includes an announcement concerning interim clinical trial results boosting BCDA stock higher. The post BioCardia News: Why BCDA Stock Is Soaring Today appeared first on InvestorPlace.

BioCardia News: Why BCDA Stock Is Soaring Today

HCA Healthcare

Pacific Biosciences of California

BioCardia (NASDAQ: BCDA) shares are trading higher. The company said it anticipates data safety monitoring board verbal feedback by the end of Dec. 15 for its pivotal Phase 3 CardiAMP Heart Failure Trial.

Why BioCardia, Pacific Biosciences And HCA Are Trading Higher Today

SAN CARLOS, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] today announced that the Company's proprietary Helix Biotherapeutic Delivery System (the Helix System) demonstrated the best safety profile among clinical transendocardial catheter injection systems used for cardiac cell therapy delivery in an in-press corrected proof published in the journal, Cardiovascular Revascularization Medicine. The Helix System is being used in the pivotal Phase III CardiAMP Heart Failure Trial currently enrolling nationwide for infusion of BioCardia's CardiAMP cell therapy to the myocardium.

BioCardia Reports Published Study Showing Helix Biotherapeutic Delivery System Used in CardiAMP Phase III Heart Failure Trial Has Fewest Adverse Events Among Competitive Delivery Systems

SAN CARLOS, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a leader in the development of autologous and allogenic cell therapies, today reported financial results and business highlights for the third quarter of 2020 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2020 with the Securities and Exchange Commission on November 10, 2020.

BioCardia Reports Third Quarter 2020 Financial Results and Business Highlights

Paper P ublished in International Journal of Cardiology D emonstrates S afety and T olerability W hile S howing F unctional I mprovement at S ix M onths

Published Peer-reviewed Initial Data from BioCardia Pivotal Phase 3 Clinical Trial of CardiAMP Demonstrates Improvement in Heart Failure Patients Measured by Exercise Outcomes and Cardiac Function

Technology May Enable Same-Day Outpatient Cell Therapy Procedures Technology May Enable Same-Day Outpatient Cell Therapy Procedures

BioCardia Issued New Patent for Delivery of Cardiac Cell Therapy Through Wrist Artery

SAN CARLOS, Calif., Aug.  26, 2020  (GLOBE NEWSWIRE) --  BioCardia®, Inc.  [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies today announced that Peter Altman, Ph.D., Biocardia’s Chief Executive Officer will give a virtual corporate presentation at the LD Micro 500 taking place online on Tuesday, September 1, 2020 at 10:20 AM ET followed by a live question and answer session with registered investors and other conference attendees.

BioCardia to Present at the LD Micro 500 Virtual Conference on September 1, 2020

SAN CARLOS, Calif., Aug.  13, 2020  (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the second quarter of 2020 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2020 with the Securities and Exchange Commission on August 13, 2020.

BioCardia Reports Second Quarter 2020 Financial Results and Business Highlights

BioCardia, Inc. (BCDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

BioCardia, Inc. (BCDA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

SAN CARLOS, Calif., Aug.  07, 2020  (GLOBE NEWSWIRE) --  BioCardia®, Inc.  [NASDAQ:BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced it will be conducting a mid-year corporate update conference call on Thursday, August 13, 2020 at 8:30AM ET. Following management’s formal remarks, there will be a question and answer session.

BioCardia To Conduct Mid-Year Conference Call and Corporate Update August 13, 2020

First Site Initiation Visit in Trial Completed and Executive Steering Committee Named First Site Initiation Visit in Trial Completed and Executive Steering Committee Named

BioCardia Announces Activation of Pivotal Trial Studying CardiAMP Cell Therapy Trial to Treat Chronic Myocardial Ischemia

SAN CARLOS, Calif., June  29, 2020  (GLOBE NEWSWIRE) --  BioCardia®, Inc. , (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the Company has resumed cases in the CardiAMP Heart Failure Trial. The first patient procedure completed since elective procedures were paused due to COVID-19 took place at Morton Plant Hospital in Clearwater, Florida this month. New consents have also taken place at additional centers.  

BioCardia Announces CardiAMP Heart Failure Pivotal Trial Continues with First Patient Randomized in COVID-19 Era

SAN CARLOS, Calif., June  17, 2020  (GLOBE NEWSWIRE) --  BioCardia®, Inc.  NasdaqCM: BCDA (the “Company”), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the pricing of its public offering of 4,762,000 shares of common stock at a price to the public of $2.10 per share. BioCardia expects to receive gross proceeds of $10 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

News for BioCardia Inc. Stock (BCDA)